News | March 28, 2026
Novartis acquires Excellergy to bolster allergy portfolio
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
The move leverages Novartis’ deep expertise in IgE biology and long-standing presence in allergic disease treatments
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
The therapy works by targeting interleukin-13, a key driver of inflammation behind eczema symptoms such as itching, skin damage, and infection
Otsuka will pay $700 million to Transcend shareholders at closing, with an additional $525 million in contingent payments tied to future sales milestones
The Trust’s shift from single-use compostable cups to a reusable system was driven by the need to reduce environmental impact and control long-term costs
The collaboration will see HNL Lab Medicine deploy Ibex’s cutting-edge AI solution, Ibex Prostate, for biopsies and transurethral resection of the prostate (TURP), boosting both diagnostic accuracy and workflow efficiency
They stressed that while the drug is clinically proven to support weight and blood sugar control, it must be prescribed only after careful patient evaluation and used under strict medical supervision.
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
It promises fewer injections for vision loss patients
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
Subscribe To Our Newsletter & Stay Updated
